カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の体外大腸がんスクリーニング検査市場（2023-2030）：検査種類別（便潜血検査、バイオマーカー検査、CRC DNAスクリーニング検査）、地域別

【英語タイトル】In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV172）・商品コード：GRV23NOV172
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：129
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：臨床診断
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,324,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

体外大腸がんスクリーニング検査市場の成長と動向
Grand View Research, Inc.の最新レポートによると、体外大腸がんスクリーニング検査の世界市場規模は、2023年から2030年にかけて年平均成長率3.02%で拡大し、2030年には11億2000万米ドルに達する見込みです。結腸・直腸悪性腫瘍の増加傾向に対抗するための新規スクリーニングモデルの増加が、市場成長に影響を与える主な要因です。腫瘍M2-PK便検査やメチル化遺伝子検査など、新たに開発された遺伝子検査やバイオマーカー検査の出現は、腫瘍診断モデルの採用率を押し上げると予測されています。

大腸悪性腫瘍の罹患率の増加は、このセグメントの成長の重要なドライバーです。例えば、国立がん研究センターが2022年6月に発表したデータによると、日本では2022年に約1,019,000人の新規がん症例が発生すると予測されており、大腸がん（CRC）は推定158,200人の新規症例を占めています。同様に、Cancer Australia が 2022 年 8 月に更新したデータによると、2022 年にオーストラリアで新たに診断される CRC の症例は 15,713 例で、男性では 8,300 例、女性では 7,413 例と予測されています。その結果、大腸悪性腫瘍の有病率の増加が大腸内視鏡検査機器の需要を促進すると予想されています。

検診を促進するための公的機関によるさまざまなイニシアチブの実施は、体外CRC検診の需要にプラスの影響を与えています。例えば、Cancer.orgの報告によると、カリフォルニア州の医療システムは2020年4月と5月の間、FITキット（糞便免疫化学検査）を提供し続け、COVID-19の流行が始まったにもかかわらず、FITの反応率は高いままでした。さらに、欧州のがんコミュニティは、COVID-19によるスクリーニングへの悪影響を評価、対処、緩和するためにリソースを動員しました。こうした努力は、体外スクリーニング検査に対する需要の持続に寄与しています。

さらに、市場成長の原動力となるのは、主要な市場参入企業による製品上市の増加です。これらの製品発売は、技術的に高度で革新的な製品へのアクセスを提供することを目的としています。例えば、Pillar Biosciences, Inc.は、2021年7月にCRC検出用のONCO/Reveal Dx Lung & Colon Cancer Assay（O/RDx-LCCA）のFDA承認を取得しました。

体外大腸がんスクリーニング検査市場レポートハイライト

- 検査タイプ別では、便潜血検査セグメントが、幅広い用途と多くの顧客層による容易な適用性により、2022年に市場で最大シェアを獲得しました。

- FOB検査セグメントのうち、免疫FOB ELISA検査が2022年に大きなシェアを占めました。免疫検査は従来のグアイアックFOB便検査よりも精度が高いためです。

- バイオマーカー検査は、非侵襲的なスクリーニング方法の出現により、予測期間中に収益シェアを拡大する見込みです。

- 腫瘍M2-PK便検査は、ScheBo Biotech AGによるScheBo腫瘍M2-PK便検査のような最近の製品導入により、2022年に最大の収益を生み出しました。

- CRCのDNAスクリーニング検査では、先進的な遺伝子スクリーニング検査であるパネルDNA検査が台頭しており、最大の収益シェアに寄与しています。

- 北米が2022年に市場の最大シェアを占めましたが、これはメラノーマ検出のための臨床ワークフローにおけるこれらの製品の高い採用率に起因しています。

- 市場で事業を展開する主要企業には、Abbott Laboratories社、Quest Diagnostics社、Siemens AG社、Randox Laboratories社、Kyowa Medex社、GeneNews社などが含まれ、市場でより高いシェアを獲得するため、常に製品の発売と地理的拡大に注力しています。

- 2022年12月、米国のGuardant Health, Inc.は、ECLIPSE研究から良好な結果が得られたことを報告しました。20,000人以上の患者を対象としたこの大規模な研究は、平均的なリスクを有する成人の大腸がん（CRC）検出におけるガーダント・ヘルス社の血液検査の有効性を評価することを目的としています。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界の体外大腸がんスクリーニング検査市場：検査タイプ別予測・動向分析
第5章. 世界の体外大腸がんスクリーニング検査市場：地域別予測・動向分析
第6章. 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Test type segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Test Type Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing incidence of colon and rectal cancers
3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
3.2.2. Market Restraint Analysis
3.2.2.1. Pending investigational evidence for certain genetic screening tests
3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Test Type Business Analysis
4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
4.2. Fecal Occult Blood Tests
4.2.1. Fecal Occult Blood Tests Market, 2018 – 2030 (USD Million)
4.2.2. Guaiac FOB Stool Test
4.2.2.1. Guaiac FOB Stool Test Market, 2018 – 2030 (USD Million)
4.2.3. Immuno-FOB Agglutination Test
4.2.3.1. Immuno-FOB Agglutination Test Market, 2018 – 2030 (USD Million)
4.2.4. Lateral Flow Immuno-FOB Test
4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2018 – 2030 (USD Million)
4.2.5. Immuno-FOB ELISA Test
4.2.5.1. Immuno-FOB ELISA Test Market, 2018 – 2030 (USD Million)
4.3. Biomarker Tests Market
4.3.1. Biomarker Tests Market, 2018 – 2030 (USD Million)
4.3.2. Tumor M2-PK Stool Test
4.3.2.1. Tumor M2-PK Stool Test Market, 2018 – 2030 (USD Million)
4.3.3. Transferrin Assays
4.3.3.1. Transferrin Assays Market, 2018 – 2030 (USD Million)
4.3.4. Immuno-FOB ELISA Test
4.3.4.1. Immuno-FOB ELISA Test Market, 2018 – 2030 (USD Million)
4.4. CRC DNA Screening Tests
4.4.1. CRC DNA Screening Tests Market, 2018 – 2030 (USD Million)
4.4.2. Methylated Gene Testing
4.4.2.1. Methylated Gene Testing Market, 2018 – 2030 (USD Million)
4.4.3. Panel DNA Tests
4.4.3.1. Panel DNA Tests Market, 2018 – 2030 (USD Million)
Chapter 5. Regional Business Analysis
5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
5.2. North America
5.2.1. SWOT Analysis
5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.2.3. U.S.
5.2.3.1. Key Country Dynamics
5.2.3.2. Target Disease Prevalence
5.2.3.3. Competitive Scenario
5.2.3.4. Regulatory Framework
5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.2.4. Canada
5.2.4.1. Key Country Dynamics
5.2.4.2. Target Disease Prevalence
5.2.4.3. Competitive Scenario
5.2.4.4. Regulatory Framework
5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3. Europe
5.3.1. SWOT Analysis
5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.3. UK
5.3.3.1. Key Country Dynamics
5.3.3.2. Target Disease Prevalence
5.3.3.3. Competitive Scenario
5.3.3.4. Regulatory Framework
5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.4. Germany
5.3.4.1. Key Country Dynamics
5.3.4.2. Target Disease Prevalence
5.3.4.3. Competitive Scenario
5.3.4.4. Regulatory Framework
5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.5. France
5.3.5.1. Key Country Dynamics
5.3.5.2. Target Disease Prevalence
5.3.5.3. Competitive Scenario
5.3.5.4. Regulatory Framework
5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.6. Italy
5.3.6.1. Key Country Dynamics
5.3.6.2. Target Disease Prevalence
5.3.6.3. Competitive Scenario
5.3.6.4. Regulatory Framework
5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.7. Spain
5.3.7.1. Key Country Dynamics
5.3.7.2. Target Disease Prevalence
5.3.7.3. Competitive Scenario
5.3.7.4. Regulatory Framework
5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Key Country Dynamics
5.3.8.2. Target Disease Prevalence
5.3.8.3. Competitive Scenario
5.3.8.4. Regulatory Framework
5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Key Country Dynamics
5.3.9.2. Target Disease Prevalence
5.3.9.3. Competitive Scenario
5.3.9.4. Regulatory Framework
5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.10. Denmark
5.3.10.1. Key Country Dynamics
5.3.10.2. Target Disease Prevalence
5.3.10.3. Competitive Scenario
5.3.10.4. Regulatory Framework
5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.11. Russia
5.3.11.1. Key Country Dynamics
5.3.11.2. Target Disease Prevalence
5.3.11.3. Competitive Scenario
5.3.11.4. Regulatory Framework
5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.3.12. Netherlands
5.3.12.1. Key Country Dynamics
5.3.12.2. Target Disease Prevalence
5.3.12.3. Competitive Scenario
5.3.12.4. Regulatory Framework
5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4. Asia Pacific
5.4.1. SWOT Analysis
5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.3. Japan
5.4.3.1. Key Country Dynamics
5.4.3.2. Target Disease Prevalence
5.4.3.3. Competitive Scenario
5.4.3.4. Regulatory Framework
5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.4. China
5.4.4.1. Key Country Dynamics
5.4.4.2. Target Disease Prevalence
5.4.4.3. Competitive Scenario
5.4.4.4. Regulatory Framework
5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.5. India
5.4.5.1. Key Country Dynamics
5.4.5.2. Target Disease Prevalence
5.4.5.3. Competitive Scenario
5.4.5.4. Regulatory Framework
5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.6. Australia
5.4.6.1. Key Country Dynamics
5.4.6.2. Target Disease Prevalence
5.4.6.3. Competitive Scenario
5.4.6.4. Regulatory Framework
5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.7. Thailand
5.4.7.1. Key Country Dynamics
5.4.7.2. Target Disease Prevalence
5.4.7.3. Competitive Scenario
5.4.7.4. Regulatory Framework
5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.4.8. South Korea
5.4.8.1. Key Country Dynamics
5.4.8.2. Target Disease Prevalence
5.4.8.3. Competitive Scenario
5.4.8.4. Regulatory Framework
5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.5. Latin America
5.5.1. SWOT Analysis
5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.5.3. Brazil
5.5.3.1. Key Country Dynamics
5.5.3.2. Target Disease Prevalence
5.5.3.3. Competitive Scenario
5.5.3.4. Regulatory Framework
5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.5.4. Mexico
5.5.4.1. Key Country Dynamics
5.5.4.2. Target Disease Prevalence
5.5.4.3. Competitive Scenario
5.5.4.4. Regulatory Framework
5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.5.5. Argentina
5.5.5.1. Key Country Dynamics
5.5.5.2. Target Disease Prevalence
5.5.5.3. Competitive Scenario
5.5.5.4. Regulatory Framework
5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.6. MEA
5.6.1. SWOT Analysis
5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.6.3. South Africa
5.6.3.1. Key Country Dynamics
5.6.3.2. Target Disease Prevalence
5.6.3.3. Competitive Scenario
5.6.3.4. Regulatory Framework
5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.6.4. Saudi Arabia
5.6.4.1. Key Country Dynamics
5.6.4.2. Target Disease Prevalence
5.6.4.3. Competitive Scenario
5.6.4.4. Regulatory Framework
5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.6.5. UAE
5.6.5.1. Key Country Dynamics
5.6.5.2. Target Disease Prevalence
5.6.5.3. Competitive Scenario
5.6.5.4. Regulatory Framework
5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
5.6.6. Kuwait
5.6.6.1. Key Country Dynamics
5.6.6.2. Target Disease Prevalence
5.6.6.3. Competitive Scenario
5.6.6.4. Regulatory Framework
5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2018 – 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market Share Analysis, 2022
6.4. Company Profiles/Listing
6.4.1. Abbott
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. Beckman Coulter Inc
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Eiken Chemical Co., Ltd.
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Epigenomics
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Sysmex Corporation
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Siemens Healthcare GmbH
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Quest Diagnostics Incorporated
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. OncoCyte Corporation
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Merck KGaA
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. Immunostics Inc.
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. Kyowa Kirin Co. Ltd.
6.4.11.1. Overview
6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.11.3. Product Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. Randox Laboratories Ltd.
6.4.12.1. Overview
6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.12.3. Product Benchmarking
6.4.12.4. Strategic Initiatives
6.4.13. R-Biopharm AG
6.4.13.1. Overview
6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.13.3. Product Benchmarking
6.4.13.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
Table 5 North America In-vitro Colorectal Cancer Screening Tests Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
Table 7 U.S. America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 8 Canada America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 9 Europe America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 10 Europe America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 11 UK America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 12 Germany America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 13 France America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 14 Italy America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 15 Spain America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 16 Sweden America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 17 Norway America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 18 Russia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
Table 19 Denmark America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 20 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
Table 21 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 22 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 23 Japan America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 24 China America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 25 India America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 26 Australia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 27 Thailand America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 28 South Korea America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 29 Latin America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 30 Latin America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 31 Brazil America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 32 Mexico America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 33 Argentina America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 34 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 35 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 36 South Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 37 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 38 UAE In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 39 UAE In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
Table 40 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 In-vitro Colorectal Cancer Screening Tests Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 In-vitro colorectal cancer screening tests market: Test type outlook and key takeaways
Fig. 15 In-vitro colorectal cancer screening tests market: Test type movement analysis & market share 2022 & 2030
Fig. 16 Global fecal occult blood tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Global guaiac FOB stool tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Immuno-FOB agglutination tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Lateral flow immuno-FOB tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Immuno-FOB ELISA tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Global biomarker tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Tumor M2-PK stool tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Transferrin assays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Global CRC DNA screening tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Methylated gene testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Panel DNA tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Regional Marketplace: Key Takeaways
Fig. 28 Regional Outlook, 2022 & 2030
Fig. 29 Regional Market Dashboard
Fig. 30 Regional Market Place: Key Takeaways
Fig. 31 North America, SWOT Analysis
Fig. 32 Europe, SWOT Analysis
Fig. 33 Asia Pacific, SWOT Analysis
Fig. 34 Latin America, SWOT Analysis
Fig. 35 MEA, SWOT Analysis
Fig. 36 North America
Fig. 37 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 38 U.S. Key Country Dynamics
Fig. 39 U.S. America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 40 Canada Key Country Dynamics
Fig. 41 Canada America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 42 Europe America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 43 UK Key Country Dynamics
Fig. 44 UK America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 45 Germany Key Country Dynamics
Fig. 46 Germany America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 47 France Key Country Dynamics
Fig. 48 France America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 49 Italy Key Country Dynamics
Fig. 50 Italy America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 51 Spain Key Country Dynamics
Fig. 52 Spain America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 53 Sweden Key Country Dynamics
Fig. 54 Sweden America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 55 Norway Key Country Dynamics
Fig. 56 Norway America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 57 Denmark Key Country Dynamics
Fig. 58 Denmark America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 59 Russia Key Country Dynamics
Fig. 60 Russia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 61 Netherlands Key Country Dynamics
Fig. 62 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 64 Japan Key Country Dynamics
Fig. 65 Japan America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 66 China Key Country Dynamics
Fig. 67 China America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 68 India Key Country Dynamics
Fig. 69 India America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 70 Australia Key Country Dynamics
Fig. 71 Australia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 72 Thailand Key Country Dynamics
Fig. 73 Thailand America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 74 South Korea Key Country Dynamics
Fig. 75 South Korea America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 76 Latin America America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 77 Brazil Key Country Dynamics
Fig. 78 Brazil America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 79 Mexico Key Country Dynamics
Fig. 80 Mexico America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 81 Argentina Key Country Dynamics
Fig. 82 Argentina America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 83 Middle East and Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 84 South Africa Key Country Dynamics
Fig. 85 South Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 86 Saudi Arabia Key Country Dynamics
Fig. 87 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 88 UAE Key Country Dynamics
Fig. 89 UAE America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 90 Kuwait Key Country Dynamics
Fig. 91 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 92 Strategy Mapping

★調査レポート[世界の体外大腸がんスクリーニング検査市場（2023-2030）：検査種類別（便潜血検査、バイオマーカー検査、CRC DNAスクリーニング検査）、地域別] (コード：GRV23NOV172)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の体外大腸がんスクリーニング検査市場（2023-2030）：検査種類別（便潜血検査、バイオマーカー検査、CRC DNAスクリーニング検査）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • インビトロがんスクリーニング検査のグローバル市場：便潜血検査、バイオマーカー検査、CRC DNAスクーリング検査
  • 世界の前立腺がん診断薬市場（2023-2030）：検査種類別（予備検査、確認検査）、種類別（腺がん、間質細胞がん）、エンドユーザー別（病院、外来施設）、地域別
  • 世界の新生児スクリーニング市場（2023-2030）：技術別（タンデム質量分析、パルスオキシメトリ）、検査種類別、製品別（装置、試薬）、地域別
  • 世界の細胞健康スクリーニング市場2023-2030：検査種類別（単一検査パネル、複数検査パネル）、サンプル種類別（血液、血清尿、唾液）、採取場所別、地域別
  • 世界の結核診断市場（2023-2030）：検査種類別（放射線法、臨床検査法、核酸検査、ファージアッセイ）、エンドユーザー別、地域別
  • 世界の医薬品無菌性試験市場（2023-2030）：製品種類別（装置、サービス）、種類別（アウトソーシング、インハウス）、検査種類別、サンプル別、エンドユーザー別、地域別
  • 世界の膵臓がん診断市場2023-2030：製品別、検査種類別（イメージング検査、生検、血液検査、その他）、がん種類別（外分泌、内分泌）、エンドユーザー別、地域別
  • 世界のロボット支援内視鏡市場（2023-2030）：用途別（病院、外来施設）、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）
  • 世界のアレルギー診断・治療市場2023-2030：製品別（器具、消耗品）、アレルゲン種類別（食品、吸入、薬剤）、検査種類別、薬剤クラス別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆